| P2093 | author name string | Borje Darpo | |
| P2860 | cites work | Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity | Q74178449 |
| | Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc | Q74180352 |
| | Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions | Q78772087 |
| | Detection of clinically significant QTc prolongation in phase I studies in healthy participants: comparison of 2 semiautomated QT measurement methods | Q79716221 |
| | Thorough QT study with recommended and supratherapeutic doses of tolterodine | Q79881692 |
| | Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents | Q81230530 |
| | Early clinical development: evaluation of drug-induced torsades de pointes risk | Q81582187 |
| | An update on QT measurement and interpretation methodologies | Q83185873 |
| | Drug induced QT prolongation and torsades de pointes | Q24673854 |
| | Quality assessment of digital annotated ECG data from clinical trials by the FDA ECG Warehouse | Q31129877 |
| | Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride | Q33147807 |
| | Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs | Q33174249 |
| | The effect of moxifloxacin on QTc and implications for the design of thorough QT studies | Q33411837 |
| | Moxifloxacin: clinical efficacy and safety | Q34189561 |
| | Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects | Q36024385 |
| | Assessment of drug-induced QT prolongation: to bin or not to bin? | Q36132399 |
| | Principles of safety pharmacology | Q36801850 |
| | Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. | Q36853529 |
| | Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. | Q37038099 |
| | Assessing proarrhythmic potential of drugs when optimal studies are infeasible. | Q37450211 |
| | A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays | Q37480106 |
| | Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. | Q39674138 |
| | Relation of QT interval measurements to evolving automated algorithms from different manufacturers of electrocardiographs | Q39759521 |
| | Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes. | Q39802290 |
| | Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. | Q39880823 |
| | Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers | Q41830782 |
| | Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study | Q42632466 |
| | Drug-induced QT prolongation in women during the menstrual cycle | Q43545871 |
| | Problems of heart rate correction in assessment of drug-induced QT interval prolongation. | Q43594994 |
| | Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects | Q44351198 |
| | Comparing methods of measurement for detecting drug-induced changes in the QT interval: implications for thoroughly conducted ECG studies. | Q44844508 |
| | Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition | Q45015196 |
| | Comparison of manual and automated measurements of the QT interval in healthy volunteers: an analysis of five thorough QT studies | Q46064743 |
| | Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies | Q46090429 |
| | Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study | Q46107330 |
| | Automated QT analysis that learns from cardiologist annotations. | Q46163338 |
| | Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine | Q46466259 |
| | Clinical assessment of drug-induced QT prolongation in association with heart rate changes | Q46498375 |
| | Effect of brivaracetam on cardiac repolarisation--a thorough QT study | Q46501773 |
| | Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval | Q46623099 |
| | QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder | Q46650430 |
| | Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study | Q46700061 |
| | Improving the detection of subtle I(Kr)-inhibition: assessing electrocardiographic abnormalities of repolarization induced by moxifloxacin | Q46732027 |
| | QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization | Q46735643 |
| | Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation | Q46839350 |
| | The influence of drug-like concepts on decision-making in medicinal chemistry | Q46922861 |
| | Man versus machine: is there an optimal method for QT measurements in thorough QT studies? | Q47337001 |
| | Gender-specific differences in the QT interval and the effect of autonomic tone and menstrual cycle in healthy adults. | Q50950526 |
| | QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. | Q51757715 |
| | ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. | Q53252784 |
| | Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. | Q53256610 |
| | International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. | Q53265213 |
| | Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects | Q57314101 |
| | Cisapride and fatal arrhythmia | Q71133416 |
| | Greater quinidine-induced QTc interval prolongation in women | Q73761390 |
| | Drug-induced prolongation of the QT interval: why the regulatory concern? | Q74178435 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 49-57 | |
| P577 | publication date | 2009-11-18 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance | |
| P478 | volume | 159 | |